Breaking News

Takeda, Altos Ink Development Pact

To further develop Altos’ ATC-1906 for the treatment of gastroparesis

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Takeda Pharmaceutical Co. and Altos Therapeutics have entered into a definitive agreement to further develop Altos’ ATC-1906 compound for the treatment of gastroparesis (GP). The agreement also includes an exclusive option for Takeda to acquire Altos following the completion of ongoing Phase I studies of ATC-1906.     GP is a chronic gastric motility disorder characterized by delayed gastric emptying. Symptoms include early satiety, post-prandial fullness, nausea, vomiting, and abdominal disco...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters